TY - JOUR
T1 - A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands
AU - Issa, Djamila E.
AU - Dinmohamed, Avinash G.
AU - Wondergem, Marielle J.
AU - Blommestein, Hedwig M.
AU - Huijgens, Peter C.
AU - Lugtenburg, Pieternella J.
AU - Visser, Otto
AU - Zweegman, Sonja
AU - Chamuleau, Martine E.D.
PY - 2021
Y1 - 2021
N2 - Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL). This study was undertaken to confirm these results in a population-based setting, with special emphasis on the value of 6xR-CHOP21 among patients aged 18–64 years. Two thousand three hundred and thirty-eight stage II–IV DLBCL patients, ≥18 years, we confirmed the similar efficacy of six versus eight cycles of R-CHOP and of R-CHOP21 versus R-CHOP14 regimens across all age groups on overall survival (median follow-up 36.4 (1.3–167.6) months). Nevertheless, overall survival decreased with older age. Interestingly, in patients 18–64 years, the adjusted risk of mortality among recipients of 6xR-CHOP21 compared to other R-CHOP regimens seems to be similar (HR 0.62; 95%CI: 0.38–1.02; p= .059). Although this finding might suggest that 6xR-CHOP21 could be considered as first-line regimen for all stage II–IV DLBCL patients, it should be confirmed in forthcoming population-based studies with larger patient numbers and longitudinal follow-up.
AB - Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL). This study was undertaken to confirm these results in a population-based setting, with special emphasis on the value of 6xR-CHOP21 among patients aged 18–64 years. Two thousand three hundred and thirty-eight stage II–IV DLBCL patients, ≥18 years, we confirmed the similar efficacy of six versus eight cycles of R-CHOP and of R-CHOP21 versus R-CHOP14 regimens across all age groups on overall survival (median follow-up 36.4 (1.3–167.6) months). Nevertheless, overall survival decreased with older age. Interestingly, in patients 18–64 years, the adjusted risk of mortality among recipients of 6xR-CHOP21 compared to other R-CHOP regimens seems to be similar (HR 0.62; 95%CI: 0.38–1.02; p= .059). Although this finding might suggest that 6xR-CHOP21 could be considered as first-line regimen for all stage II–IV DLBCL patients, it should be confirmed in forthcoming population-based studies with larger patient numbers and longitudinal follow-up.
KW - Diffuse large B-cell lymphoma
KW - R-CHOP
KW - population-based
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85096395206&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/10428194.2020.1842394
DO - https://doi.org/10.1080/10428194.2020.1842394
M3 - Article
C2 - 33213245
SN - 1042-8194
VL - 62
SP - 549
EP - 559
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -